Please scroll down the page to see other news items.
Speaker: Dr. Andrew Loblaw
Original Date: Thursday November 6, 2014
In October, 2014, the Canadian Task Force on Preventative Health Care, a body that did not include a single urologist, oncologist or prostate cancer patient, recommended against PSA testing.
The immediate reaction from Prostate Cancer Canada and virtually every recognized Canadian expert in the field was to condemn this report. Many of the statements released concluded that if governments and insurance companies accept this recommendation, more Canadian men will die unnecessarily.
This Expert Angle webinar with noted radiation oncologist and researcher Dr. Andrew Loblaw highlighted the benefits of PSA testing. In particular, Dr. Loblaw discusses:
- the importance of active surveillance and its adoption in Canada
- the need to measure baseline PSA to determine prostate cancer risk
- the use of modeling data to augment cohort data
Dr. Andrew Loblaw is a Radiation Oncologist, Clinician Scientist and Associate Professor in the Departments of Radiation Oncology and Health Policy Management and Evaluation at the University of Toronto. He has a Masters in Clinical Epidemiology from the University of Toronto and is a graduate of the Royal College’s Clinician Investigator Program. Dr. Loblaw’s clinical practice focuses on prostate cancer. He has a research interest in improving outcomes for men with prostate cancer, particularly determining the optimal timing of salvage androgen deprivation therapy, and the outcomes of active surveillance and image-guided radiotherapy. Dr. Loblaw is an Ontario Association of Radiation Oncology Clinician Scientist and a Scientist at the Sunnybrook Research Institute. He is the North American Editor for Clinical Oncology and the Co-Chair of the American Society of Clinical Oncology’s Genitourinary Advisory Group and Co-Chair of the GU group for Cancer Care Ontario’s Program in Evidence-Based Care. He has authored over 150 peer-reviewed papers and has been awarded grant funding of over $12 million dollars.
You can also view the view the video at:
Wednesday, April 30th @ 7 p.m. EST
PCCN Brampton decided long ago to increase awareness of prostate cancer by seeking out men involved in the car hobby. Our signature event each year is Cruisin' for a Cure Canada, a one-day vehicle show where we showcase cars, trucks, motorcycles and even snowmobiles in a family-friendly event. The key feature of this show, which has run every year since 2007, is to "get the boys together with their toys...and stick 'em!"
When Phil Nedham was put on "Active Surveillance" in 2010, he was already aware of our activities in this area so he approached us for sponsorship and proposed that his newly-purchased dragster be "wrapped" in black vinyl with PCCN Brampton's logo and the slogan "Early Detection Can Save Your Life...It Did Mine."
Now called "Mighty Mouse" instead of some of the other nicknames that it earned over the first few years, Phil's dragster has evolved from a stubborn vehicle that very seldom made it down the track to one that runs consistently in the top levels of its class. At its last outing in 2013, Mighty Mouse came in second. We are anticipating even better results this year.
Our member Steve Hutton has become Phil's crew chief over the years, assisted by relatives and friends, notably Alison and Trina of Kelly Shire's Angels fame.
Be sure to look us up in the pits at the seven drag racing events that are listed on the Appearance Schedule below or at either AutoFest in Oshawa, August 22 through 24 or Cruisin' for a Cure in Brampton on September 14.
Excerpted from the Janssen Inc. press release:
We are excited to share that men with metastatic castration-resistant prostate cancer (mCRPC) in Ontario now have access to a therapy that can be used prior to chemotherapy. Effective February 13, 2014, ZYTIGA® (abiraterone acetate) is being reimbursed by the public drug plan for the treatment of mCRPC in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT), who meet specific criteria. This is important news for men who want a treatment option that can be used earlier in advanced disease, helps delay disease progression, shows a consistent trend in improving overall survival and improves overall quality of life.
Men and their caregivers are encouraged to speak to their healthcare providers to learn more about the specific eligibility criteria that are required to be met for reimbursement of ZYTIGA® in Ontario.
We at Prostate Cancer Canada Network Brampton took part in a campaign to have Zytiga® approved for reimbursement for men with mCRPC in 2012, in support of Percy Bedard of Zurich, ON. Approval was granted by the ministry that Fall and Percy went on Zytiga, which helped him briefly.
It is our hope that being able to take Zytiga® after failure of ADT but before undergoing chemotherapy first might serve to spare some men from the unpleasant side effects that so often accompany chemotherapy. We do recognize that, like all available medications, Zytiga® may not work for everybody. To those for whom it does work, it could possibly lead to a longer, better life.
Steve Hutton’s Prostate Extreme Team (PET) raffled a brand new 2013 Ski Doo TNT MXZ 1200 at PET’s 9th Annual Sled Ride of Hope in Gravenhurst on Saturday, February 15th..
The winning ticket, purchased by Terry Fellner of Seguin, ON, was drawn by Rocco Rossi, President and CEO of Prostate Cancer Canada.
This year, PET raised $11,000 for Wellspring Chinguacousy and $22,000 for Prostate Cancer Canada.
All of us at Prostate Cancer Canada Network Brampton congratulate Steve, Mary and Alexis Hutton, all their volunteers and all the Sled Ride of Hope riders for their great effort this year!
You can find out more about Prostate Cancer Canada’s continuing program of expert webinars at:
The Expert Angle sessions address topics important to men with prostate cancer and their caregivers as well as the general public and clinicians. PCC uses interactive on-line technology to make leading experts in prostate cancer accessible to anyone, regardless of their location. The platform used allows PCC to communicate with individuals in a variety of settings, e.g., homes, support group meetings and community centres.
- Tuesday, December 2, 2014@ 7 p.m. EST - Dr. Howard Pai, Advances in Radiation Therapy for Prostate Cancer. Register Here.
- Tuesday, January 20, 2015@ 7 p.m. EST - Dr. Richard Casey, Subject to be announced.
- Tuesday, January 27, 2015@ 7 p.m. EST - Dr. Andrew Feifer, Subject to be announced.
- Tuesday, February 10, 2015@ 7 p.m. EST - Dr. Tetteh Ago, Subject to be announced.
- Tuesday, March 3, 2015@ 7 p.m. EST - Dr. Tae Hart, Subject to be announced.
You Tube videos of previous sessions can be accessed from http://prostatecancer.ca/Support/Expert-Angle and include:
- Dr. Tom Pickles: Prostate Cancer and the PSA Test
- Dr. Andrew Matthew: Prostate Cancer and Survivorship
- Dr. Rob Rutledge: Complete Prostate Cancer Care: What should I be doing?
- Dr. Jennifer Jones: Androgen Deprivation Therapy and Bone Health
- Dr. John Oliffe: Prostate Cancer and Masculinity
- Colleen Young: Using Social Media Safely
- Cheri Van Patten: Diet and Prostate Cancer
- Dr. Danny Vesprini: Everything You Need to Know About Active Surveillance
- Dr. Rob Bristow: The Personal Genetics of Prostate Cancer
- Dr. Shabbir Alibhai: Hormone Therapy for Prostate Cancer - cardiovascular, metabolic, and psychological side effects and how to prevent & manage them
- Dr. Hal Gunn: Tools for Optimal Health
- Dr. Daniel Santa Mina: Better to Move: Physical Activity for Men with Prostate Cancer
- Dr. Rohan Shahani: Minimally Invasive Surgical Options for Prostate Cancer: A Shifting Landscape